Skip to main content

Table 2 Severity scores of clinical symptoms related to xerosis and their effect on patient quality of life at baseline

From: An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study

Objective clinical symptoms N = 319
Severity scorea, mean (SD)  
Xerosis (n = 314) 1.7 (0.8)
Desquamation (n = 313) 1.3 (0.9)
Erythema (n = 313) 1.0 (1.0)
Total scoreb (n = 316) 4.0 (2.2)
Subjective clinical symptoms N = 319
VAS scorec, mean (SD)  
Sleep disturbance (n = 315) 2.6 (2.9)
Pruritus (n = 318) 4.3 (3.1)
Tightness of the skin (n = 316) 4.4 (3.1)
Pain (n = 314) 1.8 (2.5)
Total scored (n = 318) 13.1 (9.5)
Quality of life N = 319
DLQI scoree, mean (SD)  
Total score (n = 319) 2.7 (3.7)
  1. Abbreviations: DLQI Dermatology Life Quality Index, N number of patients in the whole study population, n number of patients for which data were collected, SD standard deviation, VAS visual analog scale. aA four-point severity scale from 0 (no signs) to 3 (severe) was used by the physician to assess each objective clinical symptom. bTotal score scale ranged from 0 to 9. cVAS score was assessed by the patient and the scale of each symptom ranged from 0 (absence) to 10 (very severe). dTotal VAS score scale ranged from 0 to 40. eDLQI total score scale ranged from 0 (no effect at all on patient’s life) to 30 (extremely large effect on patient’s life)